Released May 3, 2024, before the open
10-Q filed May 3, 2024, 33 days after period end · 0001785530-24-000020
Q1 2024 · 10-Q
Revenue—
Net Income-$16.19M-$16.19M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.39-$0.39 N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$17,162,000N/M
Operating Cash Flow-$15,297,000N/M
Free Cash Flowderived-$15,408,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$16.19M | -$11.98M | -$15.34M | -$7.44M |
| EPS Diluted | -$0.39 | -$0.34 | -$0.56 | -$83.36 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR